Science and Health

Yale IDs gene mutation links to hypertension

(Xinhua)
Updated: 2011-02-11 09:06
Large Medium Small

WASHINGTON - Yale University researchers have identified two novel genetic mutations that can trigger hypertension in up to a third of patients suffering from a common cause of severe high blood pressure, according to a report to be published Friday in journal Science.

Related readings:
Yale IDs gene mutation links to hypertension Too much fructose could raise your blood pressure
Yale IDs gene mutation links to hypertension Popular energy drinks have hidden risks: Study
Yale IDs gene mutation links to hypertension Control blood pressure w/ whole grains
Yale IDs gene mutation links to hypertension Hypertension kills over 1m Chinese each year: Study

The findings are a major step in understanding the causes of high blood pressure, which afflicts one out of every three Americans, said Richard Lifton, chair of the Department of Genetics and senior author of the paper. These findings may lead to a genetic screening test for this common cause of severe hypertension, he said.

Five to ten percent of patients with severe hypertension have tumors of the adrenal gland that produce a hormone called aldosterone. Removing these tumors can cure this form of hypertension.

Sifting for clues by sequencing all of the genes from these tumors, and comparing their sequences to the patients' normal DNA, the researchers found that either one of two mutations of a single gene were found in eight of 22 tumors studied.

The investigators discovered that these mutations cause both aldosterone release and tumor formation by allowing the encoded protein, a potassium channel, to conduct sodium rather than only allowing potassium to pass through the channel.

In addition to causing these adrenal tumors, inherited mutations in the same gene were also found to be the cause of a rare familial form of severe hypertension.

The results underscore the value of whole exome sequencing, or decoding of all of a patient's genes rather than just a few suspect gene targets, said Lifton, who is also an investigator for the Howard Hughes Medical Institute.

"This gene was not on anybody's list to sequence in an investigation of this disease," Lifton said. "We really hit the jackpot."

分享按钮